Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
One price watchdog group says no.
The FDA approved Gilead's novel cancer-fighting gene therapy.
The price of the drug, which is to be administered just once to each patient, will be $373,000.
They're more popular than ever, even though the political winds are against them.
FDA approves Novartis treatment that reengineers human cells to kill cancer